ITP
TEVA icon

Iron Triangle Partners’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Iron Triangle Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,217,730
Closed -$34.1M – 36
2025
Q1 		$34.1M Buy
2,217,730
+17,694
+0.8% +$316K 5.37% 4
2024
Q4 		$48.5M Buy
2,200,036
+256,246
+13% +$4.66M 5.34% 6
2024
Q3 		$35M Sell
1,943,790
-1,356,395
-41% -$23.7M 4.85% 8
2024
Q2 		$53.6M Buy
3,300,185
+530,321
+19% +$8.17M 5.45% 7
2024
Q1 		$39.1M Buy
2,769,864
+1,469,864
+113% +$18.5M 4% 12
2023
Q4 		$13.6M Buy
+1,300,000
New +$12.1M 1.76% 25
2020
Q2 		– Sell
-1,000,000
Closed -$8.98M – 33
2020
Q1 		$8.98M Buy
+1,000,000
New +$10.2M 3.47% 13

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Iron Triangle Partners's TEVA Position: Q2 2025 in Review

Iron Triangle Partners sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2025, closing a stake of 2,217,730 shares — an estimated $34.1M sold.

Iron Triangle Partners first reported a position in TEVA in Q1 2020 and held it in 7 quarters. The position peaked at $53.6M in Q2 2024. 540 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Iron Triangle Partners reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2025 after selling out during the quarter.
  • Iron Triangle Partners sold 2,217,730 Teva Pharmaceutical Industries Limited shares in Q2 2025, an estimated $34.1M.
  • Iron Triangle Partners first reported a position in Teva Pharmaceutical Industries Limited in Q1 2020 and held it in 7 quarters.
  • Iron Triangle Partners's Teva Pharmaceutical Industries Limited position peaked at $53.6M in Q2 2024.
  • 540 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2025.

Based on Iron Triangle Partners's 13F filing for Q2 2025, filed 14 Aug 2025.